A warm welcome to our new Independent #BoD Chair, R. Scott Greer, whose deep operational expertise and experience founding, growing, and advising #Biotech success stories will be an enormous help to us in our journey to help patients and families with #neurodegenerative diseases! bit.ly/48X23gP

We are honored to announce the formation of our #ScientificAdvisoryBoard, an extraordinary group of pioneers in #neurological and #MovementDisorders and renowned global leaders who will guide our scientific strategy.
bit.ly/48ZitGF
#ParkinsonsDisease #neurodegenerative #Biotech

We are excited to welcome Jeff Kasten to the Vertero team as our Chief Business Officer! Jeff brings a wealth of experience in the #LifeSciences space and will be instrumental in accelerating our portfolio strategy in #neurodegenerative diseases. bit.ly/449Av6m
#Biotech #ParkinsonsDisease

Exciting news today as we initiate our Phase 1 trial of VT-5006, a first-in-class, gut-selective small molecule for the treatment of #ParkinsonsDisease!

bit.ly/3K7k4AM #ClinicalTrials #Biotech

We are exploring beyond the #brain to develop differentiated therapies for challenging #neurodegenerative diseases. Our passion is to change the perception and treatment of to delay progression and preserve quality of life as long as possible.
Learn more www.vertero.com
#ParkinsonsDisease #biotech

We are Vertero! Refreshing our look and our focus to break barriers in the treatment of #neurodegenerative diseases. Take a look at our story and our mission here:
New website: www.vertero.com
Press Release: bit.ly/49cBC8r
#biotech #ParkinsonsDisease #Rebrand